Next-generation IHC for BRAF V600E and RAS Q61R have been employed to identify the molecular drivers of ATC, showing diffuse weak to moderate expression in the tumor cytoplasm (Fig. 6A to B). The gene discussed is BRAF; the disease is neoplasm.